Virtu Financial LLC Acquires New Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Virtu Financial LLC acquired a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 3,599 shares of the company’s stock, valued at approximately $640,000.

Several other hedge funds and other institutional investors have also bought and sold shares of KRYS. Jennison Associates LLC lifted its stake in shares of Krystal Biotech by 112.5% in the 4th quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock worth $89,862,000 after purchasing an additional 383,495 shares during the period. First Turn Management LLC bought a new position in shares of Krystal Biotech in the 4th quarter worth approximately $30,045,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Krystal Biotech by 54.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after purchasing an additional 231,255 shares during the period. Eventide Asset Management LLC bought a new position in shares of Krystal Biotech in the 4th quarter worth approximately $16,932,000. Finally, TimesSquare Capital Management LLC lifted its stake in shares of Krystal Biotech by 103.6% in the 4th quarter. TimesSquare Capital Management LLC now owns 250,470 shares of the company’s stock worth $31,073,000 after purchasing an additional 127,435 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

Krystal Biotech stock traded down $6.84 during trading hours on Friday, hitting $191.94. 472,143 shares of the stock traded hands, compared to its average volume of 377,663. Krystal Biotech, Inc. has a 1 year low of $93.95 and a 1 year high of $219.34. The stock has a market capitalization of $5.48 billion, a price-to-earnings ratio of 100.53 and a beta of 0.84. The firm’s 50 day moving average price is $184.55 and its 200-day moving average price is $162.86.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17). The business had revenue of $45.25 million during the quarter, compared to the consensus estimate of $47.37 million. During the same quarter in the prior year, the company earned ($1.76) EPS. The company’s quarterly revenue was up 452400.0% compared to the same quarter last year. Research analysts forecast that Krystal Biotech, Inc. will post 2 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. HC Wainwright restated a “buy” rating and set a $200.00 target price on shares of Krystal Biotech in a research note on Monday, May 6th. Stifel Nicolaus restated a “buy” rating and set a $204.00 target price (up previously from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $177.63.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the sale, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Krystal Biotech news, Director Julian S. Gangolli sold 20,000 shares of the firm’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total value of $4,394,000.00. Following the sale, the insider now directly owns 1,525,882 shares of the company’s stock, valued at approximately $268,189,020.32. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).